A Sahbaz1, K Gungorduk2, V Gulseren3, I A Ozdemir4, M Harma5, M Harma5, M Sancı2. 1. Zonguldak Bulent Ecevit University School of Medicine, Department of Obstetrics and Gynecology, Zonguldak, Turkey. 2. Izmir Tepecik Research and Training Hospital, Department of Gynecology and Oncology, Izmir, Turkey. 3. Izmir Tepecik Research and Training Hospital, Department of Obstetrics and Gynecology, Izmir, Turkey. 4. Bakirkoy Sadi Konuk Research and Training Hospital, Department of Gynecology and Oncology, Istanbul, Turkey. 5. Zonguldak Bulent Ecevit University School of Medicine, Department of Obstetrics and Gynecology & Obstetrics and Gynecology, Zonguldak, Turkey.
Abstract
Aim: Lymphocyst is one of the most common complications of lymphadenectomy and generally encountered during uro-gynecological oncology surgeries. We aimed to define the risk factors for formation of a lymphocyst in patients with various gynecological cancer types in whom a lymphadenectomy was performed. Methods: This retrospective study was performed on 206 patients. Of the 206 patients, 100 were diagnosed with a lymphocyst, and 106 were assigned to a control group. Laboratory findings and surgical characteristics of the patients were compared. Results: No differences were observed in age, pre-operative hemoglobin; platelet, white blood cell, and lymphocyte counts; or pre-operative albumin level (p = 0.315, 0.500, 0.525, 0.683, 0.740, and 0.97, respectively). A significant effect of the heparin dose × heparin days interaction and lymphocyst formation was observed (p = 0.002). Lymphocysts were most frequently detected in the ovarian cancer subgroup (49 %). Significant differences were detected between the groups in the percentages of patients who underwent CT only and RT only treatments (p = 0.001 and 0.002, respectively). The logistic regression analysis revealed a relationship between the LMWH dose × days interaction and formation of a lymphocyst (OR, 1.10; 95 % CI, 1.0-1.13; p = 0.01). Conclusion: The association between total LMWH dose administered and the formation of lymphocysts in patients with gynecological pelvic cancer was investigated for the first time. Significant relationship between heparin dose × days and lymphocyst formation was found. Although anticoagulation with LMWH is essential for preventing thromboembolism, it should be used appropriately to prevent other complications, such as bleeding and lymphocysts.
Aim: Lymphocyst is one of the most common complications of lymphadenectomy and generally encountered during uro-gynecological oncology surgeries. We aimed to define the risk factors for formation of a lymphocyst in patients with various gynecological cancer types in whom a lymphadenectomy was performed. Methods: This retrospective study was performed on 206 patients. Of the 206 patients, 100 were diagnosed with a lymphocyst, and 106 were assigned to a control group. Laboratory findings and surgical characteristics of the patients were compared. Results: No differences were observed in age, pre-operative hemoglobin; platelet, white blood cell, and lymphocyte counts; or pre-operative albumin level (p = 0.315, 0.500, 0.525, 0.683, 0.740, and 0.97, respectively). A significant effect of the heparin dose × heparin days interaction and lymphocyst formation was observed (p = 0.002). Lymphocysts were most frequently detected in the ovarian cancer subgroup (49 %). Significant differences were detected between the groups in the percentages of patients who underwent CT only and RT only treatments (p = 0.001 and 0.002, respectively). The logistic regression analysis revealed a relationship between the LMWH dose × days interaction and formation of a lymphocyst (OR, 1.10; 95 % CI, 1.0-1.13; p = 0.01). Conclusion: The association between total LMWH dose administered and the formation of lymphocysts in patients with gynecological pelvic cancer was investigated for the first time. Significant relationship between heparin dose × days and lymphocyst formation was found. Although anticoagulation with LMWH is essential for preventing thromboembolism, it should be used appropriately to prevent other complications, such as bleeding and lymphocysts.
Authors: P Benedetti-Panici; F Maneschi; G Cutillo; G D'Andrea; V S di Palumbo; M Conte; G Scambia; S Mancuso Journal: Gynecol Oncol Date: 1997-06 Impact factor: 5.482
Authors: J Schmitges; Q-D Trinh; L Jonas; L Budäus; R Larbig; T Schlomm; P I Karakiewicz; H Heinzer; H Huland; M Graefen; T Steuber Journal: Eur J Surg Oncol Date: 2012-08-17 Impact factor: 4.424
Authors: K Fujiwara; J Kigawa; K Hasegawa; R Nishimura; N Umezaki; M Ando; H Itamochi; S Yamaguchi; T Oda; N Terakawa; I Kohshima; I Kohno Journal: Int J Gynecol Cancer Date: 2003 Jan-Feb Impact factor: 3.437